Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance

Kang Li, Yingtao Liao, Zhihua Yang, Caishuang Yang, Minhua Chen, Xiuhua Wu, Zhaoyu GanFrontiers in Psychiatry 2021 · DOI

Abstract

Background: Medication non-adherence is prevalent in patients with bipolar disorder (BD). Long-acting injectable antipsychotics (LAIAs) are widely used to improve compliance with treatment. This study aimed to illustrate the effectiveness, compliance, and safety profile of once-monthly paliperidone palmitate (PP1M), a novel therapeutic LAIA, in the management of bipolar I disorder (BDI). Method: A prospective follow-up was arranged to 11 BDI patients who were prescribed PP1M as monotherapy or adjunctive treatment. Severity of symptoms, disturbing behavior, status of employment, 17-item Hamilton Depression Rating Scale (HAMD-17), and Young Mania Rating Scale (YMRS) were evaluated at the baseline and the endpoint of follow-up. Clinical Global Impression-Bipolar Disorder-Severity of Illness Scale (CGI-BP) and Treatment Emergent Symptom Scale (TESS) were measured at each injection of PP1M. Compliance, relapse or switch, and new hospitalization were monitored through the period of follow-up. Results: The median duration of treatment was 14 months, ranging from 5 to 22 months. The scores (mean ± standard deviation) of HAMD-17, YMRS, and CGI-BP generally decreased from the baseline (16.1 ± 10.3, 30.9 ± 12.6, 5.3 ± 0.7) to the endpoint (7.4 ± 5.7, 3.7 ± 3.2, 2.3 ± 0.7). No disturbing behavior was detected at the endpoint. Neither new hospitalization nor manic/mixed episode occurred during treatment, whereas mild to moderate depressive episodes were reported in three cases. The status of employment of 10 participants (90.9%) was improved, and no new safety concern was detected. Conclusion: PP1M might offer a new valid treatment option in the long-term management of BDI, especially for those with poor compliance with oral medication. However, more studies are needed to further justify such role.

Introduction

Bipolar Disorder (BD) is a chronic, life-altering condition characterized by extreme mood swings. While effective pharmacological treatments exist, they only work if patients take them. Unfortunately, medication non-adherence is a massive hurdle in psychiatric care, with rates ranging from 20% to 60%. For patients with Bipolar I Disorder (BDI), missing doses often leads to rapid relapse, hospitalization, and increased suicide risk.

Long-acting injectable antipsychotics (LAIAs) offer a solution by replacing daily pills with a single monthly injection administered by a healthcare professional. While LAIAs are standard for schizophrenia, their role in BDI—especially for patients with a history of non-compliance—is less established. This paper investigates whether paliperidone palmitate (PP1M) can provide the long-term stability these "difficult-to-treat" patients need.

Methods

The authors conducted a prospective, open-label, one-arm observational study following 11 BDI patients recruited from the Third Affiliated Hospital of Sun Yat-sen University. These patients had a documented history of non-compliance or a stated unwillingness to take oral medication.

Patients received PP1M either as monotherapy or adjunctive treatment. The dosing regimen involved an initial loading phase (150 mg then 100 mg), followed by flexible monthly maintenance doses. Clinical evaluation utilized standard psychiatric tools: the 17-item Hamilton Depression Rating Scale (HAMD-17) for depression, the Young Mania Rating Scale (YMRS) for mania, and the Clinical Global Impression-Bipolar Disorder-Severity of Illness Scale (CGI-BP) for overall severity. Researchers also tracked "disturbing behaviors" (e.g., suicide attempts, fighting) and employment status over a median follow-up of 14 months.

Results

The quantitative improvements were stark across all primary psychiatric scales. The transition from baseline to endpoint showed a significant reduction in symptom severity and a stabilization of mood across the cohort.

Distribution of CGI-BP scores over successive PP1M injections.

As shown in Figure 1, the CGI-BP scores for all 11 cases demonstrated a consistent downward trend, stabilizing at lower levels of illness severity after the initial injections. Specifically, the mean CGI-BP score improved from 5.3 (severely ill) at baseline to 2.3 (bordering on normal/mildly ill) at the study endpoint.

Comparison of clinical metrics at baseline and study endpoint.

Table 3 details the individual patient outcomes. Mania (YMRS) scores dropped from a baseline mean of 30.9 to 3.7, and depression (HAMD-17) scores decreased from 16.1 to 7.4. Notably, there were zero new hospitalizations during the treatment period. Furthermore, the treatment had a profound impact on functional recovery: 10 out of 11 participants (90.9%) improved their employment or school status, with several moving from unemployment to full-time work.

Key Insights

  • Closing the Compliance Gap: PP1M effectively removed the burden of daily medication adherence. By ensuring consistent therapeutic blood levels, the drug prevented the "cycling" often triggered by missed oral doses.
  • Asymmetric Efficacy: While no manic or mixed episodes occurred, three patients experienced mild-to-moderate depressive episodes, suggesting PP1M may be more potent at preventing mania than depression.
  • Safety and Tolerability: Side effects were consistent with the known profile of paliperidone (sedation, weight gain). Crucially, no patients discontinued treatment due to safety concerns.

Discussion

The findings suggest that PP1M is a promising option for long-term BDI management, particularly for patients with poor oral medication compliance. However, the study has limitations, including a small sample size (n=11) and the lack of a control group. The open-label nature and selection bias toward non-compliant patients also limit the generalizability of the results.

Future research should involve larger, randomized controlled trials (RCTs) to validate these findings and compare PP1M directly against other long-acting injectables and oral maintenance therapies.

Summary updated

Abstract

<b>Background:</b> Medication non-adherence is prevalent in patients with bipolar disorder (BD). Long-acting injectable antipsychotics (LAIAs) are widely used to improve compliance with treatment. This study aimed to illustrate the effectiveness, compliance, and safety profile of once-monthly paliperidone palmitate (PP1M), a novel therapeutic LAIA, in the management of bipolar I disorder (BDI). <b>Method:</b> A prospective follow-up was arranged to 11 BDI patients who were prescribed PP1M as monotherapy or adjunctive treatment. Severity of symptoms, disturbing behavior, status of employment, 17-item Hamilton Depression Rating Scale (HAMD-17), and Young Mania Rating Scale (YMRS) were evaluated at the baseline and the endpoint of follow-up. Clinical Global Impression-Bipolar Disorder-Severity of Illness Scale (CGI-BP) and Treatment Emergent Symptom Scale (TESS) were measured at each injection of PP1M. Compliance, relapse or switch, and new hospitalization were monitored through the period of follow-up. <b>Results:</b> The median duration of treatment was 14 months, ranging from 5 to 22 months. The scores (mean ± standard deviation) of HAMD-17, YMRS, and CGI-BP generally decreased from the baseline (16.1 ± 10.3, 30.9 ± 12.6, 5.3 ± 0.7) to the endpoint (7.4 ± 5.7, 3.7 ± 3.2, 2.3 ± 0.7). No disturbing behavior was detected at the endpoint. Neither new hospitalization nor manic/mixed episode occurred during treatment, whereas mild to moderate depressive episodes were reported in three cases. The status of employment of 10 participants (90.9%) was improved, and no new safety concern was detected. <b>Conclusion:</b> PP1M might offer a new valid treatment option in the long-term management of BDI, especially for those with poor compliance with oral medication. However, more studies are needed to further justify such role.
BibTeX
@inproceedings{li2021case,
  author = {Kang Li and Yingtao Liao and Zhihua Yang and Caishuang Yang and Minhua Chen and Xiuhua Wu and Zhaoyu Gan},
  title = {{Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance}},
  booktitle = {Frontiers in Psychiatry},
  year = {2021},
  doi = {10.3389/fpsyt.2020.529672},
}
Figure